(Certain presentations are available by clicking on titles below)
8:15
Welcome and introduction
Giorgio V. Scagliotti, MD, PhD and Johan Vansteenkiste, MD, PhD
Session I: Diagnosis and staging
Moderators: Pieter E. Postmus, MD, PhD and Johan Vansteenkiste, MD, PhD
8:30
The new staging system for lung cancer
Peter Goldstraw, MD, FRCS
8:50
Non invasive staging techniques
Johan F. Vansteenkiste, MD, PhD
9:10
Minimally invasive and invasive staging techniques
Speaker invited
9:30
Pathological assessment of diagnostic specimens
Keith M. Kerr, FRCPath
9:50
Clinical case: TNM staging quiz
Vincent Ninane, MD, PhD
10:10
Coffee break
Session II: Surgery
Moderators: Rafael Rosell, MD and Giorgio V. Scagliotti, MD, PhD
10:40
Surgery for screening detected lesions
Ugo Pastorino, MD
11:00
The evolving role of adjuvant therapies (includes cytotoxic and others)
Rafael Rosell, MD, PhD
11:20
Can we expand the role of surgery in stage III NSCLC?
Paul E. Van Schil, MD, PhD
11:40
Pancoast tumors: the case for multidisciplinary approach
Dominique Grünewald, MD
12:00
Clinical case (Pancoast): The challenge of superior sulcustumors
Paul R. De Lyen, MD, PhD
12:20
Adjourn
13:00 - 14:00
Roche supported Lunch Symposium
Session III: Role of radiotherapy in lung cancer
Moderators: Pieter E. Postmus, MD, PhD and Paul Van Houtte, MD, PhD
14:20
The evidence for concurrent CT+RT in stage IIIB disease
Paul Van Houtte, MD, PhD
14:40
Management of toxicities of RT+CT
Francoise Mornex, MD
15:00
Stereotactic RT in lung cancer
Frank J. Lagerwaard, MD, PhD
15:20
Targeted therapies in locally advanced NSCLC
Wilfried Eberhardt, MD
15:40
Clinical case: Do we need biopsy to treat early inoperable
lung cancer?
Frank J. Lagerwaard, MD, PhD
16:00
Coffee break
Session IV: Neuro-endocrine lung tumours
Moderators: Egbert Smit, MD, PhD and Johan Vansteenkiste, MD, PhD
16:30
The pathological spectrum of neuro-endocrine lung tumours
Mauro Papotti, MD
16:50
Therapy with radiolabelled somatostatin analogues in bronchial carcinoids
Martijn van Essen, MD
17:10
Large cell neuroendocrine carcinoma
William D. Travis, MD, MSKCC
17:30
SCLC: developments in systemic treatment
Egbert Smit, MD, PhD
17:50
Adjourn
Saturday, 7 March 2009
8:00
Welcome and introduction
Pieter E. Postmus, MD, PhD and Paul Van Houtte, MD, PhD
Session V: Supportive care optimization
Moderators: Peter G. Harper, MD, FRCP and Paul Van Houtte, MD, PhD
8:10
Management of pleural effusion
Kristiaan Nackaerts, MD, PhD
8:30
Treatment and prevention of bone metastases
Peter G. Harper, MD, FRCP
8:50
Anemia
Johan F. Vansteenkiste, MD, PhD
9:10
Interventional bronchoscopy for the management of endobronchial lesions
Tom G. Sutedja, MD, PhD, FCCP
9:30
Clinical case: When and how to manage brain metastases
Wilfried Eberhardt, MD
9:50
Coffee Break
10:20
Antifolates in front line non-small cell lung cancer
Giorgio V. Scagliotti, MD, PhD
Session VI: Changing the treatment paradigms in front line metastatic NSCLC
Moderators: Christian Manegold, MD and Giorgio V. Scagliotti, MD, PhD
10:40
Bevacizumab- based chemotherapy in advanced non-small cell lung cancer
Speaker invited
11:00
Monoclonal antibodies against EGFR in Non-small cell lung cancer
Robert Pirker, MD
11:20
Special populations (never smokers, PS2)
Lucio Crinò, MD
11:40
Clinical case: Targeted therapies with or without chemotherapy
Robert Pirker, MD
12:00
Pfizer supported Lunch Symposium
Session VII: Where do we stand with Biomarkers?
Moderator: Johan Vansteenkiste, MD, PhD
13:30
Biomarker for efficacy of EGFR- inhibiting agents: an update
Federico Cappuzzo, MD
13:50
Biomarker of efficacy of antiangiogenic agents
Rafael Rosell, MD, PhD
14:10
Mechanisms of resistance to antineoplastic agents
Miguel Taron, PhD
14:30
Functional imaging in predicting the response to antineoplastic agents
Silvia Novello, MD
14:50
Clinical case: Is it possible to select treatment based on biomarkers?
Silvia Novello, MD
Session VIII: Mesothelioma
Moderators: Paul Van Houtte, MD, PhD and Walter Weder, MD
15:10
Mesothelioma: The standard of care
Jan van Meerbeeck, MD, PhD
15:30
The controversial role of surgery in malignant pleural mesothelioma
Walter Weder, MD
15:50
Future developments in the management of malignant pleural mesothelioma
Dean A. Fennel, MD, PhD
16:00
Adjourn
©2008 Imedex®, LLC. All rights reserved. Reproduction in whole or part is prohibited without prior written consent from Imedex and contributing faculty.